HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:7/14/2017)... ... 2017 , ... Sonic Manufacturing Technologies is proud to be ... solar system on its roof top. “We will be independent of the grid ... stated. The company’s proud history of social responsibility and participation in the preservation ...
(Date:7/14/2017)... Maine (PRWEB) , ... July 13, 2017 , ... ... D-Dimer linearity and calibration verification test kit has received US FDA 510 (k) ... in a human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... Thousands of ... and August for the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete ... to earn spots on US teams that participate in world championships. , RC Pylon ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... the completion of a major transaction with Eurazeo PME. The reputable French private ... alliance fuels In’Tech Medical’s service offerings while leveraging the company’s manufacturing expertise and ...
Breaking Biology Technology:
Cached News: